Growth Metrics

Outlook Therapeutics (OTLK) Return on Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Return on Equity for 7 consecutive years, with 2.68% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 69.0% to 2.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.68% through Dec 2025, up 69.0% year-over-year, with the annual reading at 1.66% for FY2019, 64.0% up from the prior year.
  • Return on Equity for Q4 2025 was 2.68% at Outlook Therapeutics, down from 2.97% in the prior quarter.
  • The five-year high for Return on Equity was 2.97% in Q3 2025, with the low at 1.85% in Q1 2025.